This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
The Zacks Analyst Blog Highlights Meta Platforms, Becton Dickinson, CME Group, Chipotle Mexican Grill and ParkerHannifin
by Zacks Equity Research
Meta Platforms, Becton Dickinson, CME Group, Chipotle Mexican Grill and ParkerHannifin are included in this Analyst Blog.
Top Analyst Reports for Meta Platforms, Becton Dickinson & CME Group
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Meta Platforms, Inc. (META), Becton, Dickinson and Company (BDX) and CME Group (CME).
3 Dental Supplies Stocks to Watch Amid Industry Headwinds
by Indrajit Bandyopadhyay
Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, MCK and ABC.
SmileDirectClub (SDC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SmileDirectClub (SDC) delivered earnings and revenue surprises of 18.18% and 7.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AmerisourceBergen (ABC) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 0.78% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Lags Q2 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -1.14% and 0.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights The Walt Disney, Broadcom, PayPal Holdings, Becton, Dickinson and Norfolk Southern
by Zacks Equity Research
The Walt Disney, Broadcom, PayPal Holdings, Becton, Dickinson and Norfolk Southern are part of the Zacks top Analyst Blog.
Here's How Much a $1000 Investment in Becton Dickinson Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Top Research Reports for Walt Disney, Broadcom & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Broadcom Inc. (AVGO) and PayPal Holdings, Inc. (PYPL).
BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence
by Zacks Equity Research
BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.
BD's (BDX) New Cloud Software Solution to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.
BD's (BDX) Latest Monkeypox PCR Assay Commercially Available
by Zacks Equity Research
BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.
Quest Diagnostics (DGX) & Peers Progress With Monkeypox Testing
by Zacks Equity Research
Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.
BD's (BDX) Latest PFS Launch to Boost Production Efficiencies
by Zacks Equity Research
BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.
Implied Volatility Surging for BD (BDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BD (BDX) stock based on the movements in the options market lately.
Here's Why You Should Hold on to BD (BDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
BD's (BDX) Latest Collaboration to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.
BD (BDX) Ties Up With LabCorp to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.
Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
by Zacks Equity Research
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View
by Zacks Equity Research
QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.